CITIUS ONCOLOGY, INC. — Form 8-K
Filed August 12, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Citius Oncology announced the appointment of Jonathan Peri, Ph.D., J.D., as an independent director effective August 10, 2026, expanding the board to nine members. Peri brings 30 years of experience in higher education, financial services, law, and corporate governance, including roles as President of Manor College and former General Counsel of Neumann University. The board determined he qualifies as independent under Nasdaq listing standards.
Why this rating
Routine board expansion. Governance strengthening is positive but no material financial, operational, or strategic change to a $5.1M company.
See more from August 12, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.